Skip to main content
. 2020 Jun 24;21(8):1007–1017. doi: 10.3348/kjr.2020.0485

Table 1. Predominant Clinical Findings of Patients with COVID-19.

Characteristics Training Cohort (n = 166) Validation Cohort (n = 72) P
Age (years) 43.8 ± 12.3 45.1 ± 15.8 0.567
Sex (male/female ratio) 103/63 38/34 0.233
Duration (days) 3 (0–8) 4 (0–7) 0.306
Epidemiological history (%) 0.203
 Direct exposure history 86 (51.8) 29 (40.3)
 Indirect exposure history 47 (23.3) 28 (38.9)
 No exposure history 33 (19.9) 15 (20.8)
Symptoms (%) 0.871
 Fever 132 (79.5) 50 (69.4)
 Cough 86 (51.8) 31 (43.1)
 Fatigue 24 (14.5) 9 (12.5)
 Chest distress 19 (11.5) 7 (9.7)
 Diarrhea 5 (3.0) 3 (4.2)
 Headache 7 (4.2) 2 (2.8)
 None 5 (3.0) 3 (4.2)
Underlying comorbidity (%) 0.565
 Endocrine system disease 20 (12.0) 10 (13.9)
 Cardiovascular and cerebrovascular disease 15 (9.0) 6 (8.3)
 Digestive system disease 12 (7.2) 5 (6.9)
 Malignancy 4 (2.4) 2 (2.8)
 Mental disease 1 (0.6) 1 (1.4)
 Urinary system disease 7 (4.2) 3 (4.2)
 Respiratory system disease 2 (1.2) 0 (0.0)
 None 112 (67.5) 52 (72.2)
White blood cell count (x 109/L) 5.11 (1.99–10.17) 5.72 (2.60–14.24) 0.081
Lymphocyte count (x 109/L) 1.10 (0.43–2.15) 1.34 (0.41–2.81) < 0.001*
C-reactive protein (mg/L) 12.80 (0.49–198.10) 9.80 (0.35–156.90) 0.191
Procalcitonin (ng/mL) 0.04 (0.00–0.91) 0.03 (0.01–0.94) 0.499
Alanine aminotransferase (U/L) 24.50 (6.00–363.90) 23.00 (6.00–267.00) 0.339
Aspartate aminotransferase (U/L) 27.00 (9.60–208.20) 25.00 (8.20–218.00) 0.106
Therapeutic strategy (%) 0.424
 Antiviral therapy 149 (89.7) 64 (88.9)
 Antibiotic treatment 102 (61.5) 35 (56.9)
 Oxygen inhalation 52 (31.3) 21 (29.2)
 Interferon therapy 18 (10.8) 8 (11.1)
 Glucocorticoid therapy 16 (9.6) 3 (4.2)

*p < 0.050. COVID-19 = coronavirus disease